Key Takeaways
- SK Hynix (SKHY) raised $26.5 billion in its U.S. American Depositary Receipt (ADR) debut, marking the largest-ever initial share sale by a foreign company in the United States.
- Moderna (MRNA) shares sank 11% to $68.50, marking the stock's worst single-day performance since May 2025 following a sector-wide biotech rotation and a JPMorgan sell rating.
- Elon Musk has directed Tesla (TSLA) staff to prioritize the use of Grok, xAI’s chatbot, while imposing a $200-per-week cap on third-party AI tool spending.
- Coca-Cola Consolidated (COKE) declared a $0.25 per share third-quarter dividend, maintaining its 55-year streak of consecutive payments.
SK Hynix Makes Historic Wall Street Entrance
South Korean chipmaker SK Hynix (SKHY) successfully priced its U.S. offering at $149 per ADR, raising a staggering $26.5 billion. The offering was more than seven times oversubscribed, reflecting intense investor appetite for the primary supplier of high-bandwidth memory (HBM) chips used in Nvidia (NVDA) AI processors.
The stock surged 13.1% in its first day of trading on the Nasdaq, closing at $168.49. This blockbuster listing surpasses the 2014 record held by Alibaba (BABA) and trails only SpaceX in terms of total U.S. capital raised this year. Analysts suggest the move will help narrow the valuation gap between SK Hynix and its U.S. rival, Micron (MU).
Biotech Rout Wipes Out Moderna Gains
Moderna (MRNA) experienced a sharp 11% decline on Friday, leading a broader sell-off in the biotechnology sector. The drop comes despite recent bullish news regarding its seasonal flu vaccine, mRNA-1010, which remains on track for an FDA decision by August 5.
Market experts attributed the slump to aggressive profit-taking following a 48% rally in June and a cautious note from JPMorgan (JPM), which reaffirmed its "Sell" rating. Other biotech players also suffered, with ImmunityBio (IBRX) and Sarepta Therapeutics (SRPT) both falling roughly 8% as investors rotated out of high-growth medical research stocks.
Musk Tightens AI Spending at Tesla
Elon Musk has implemented new cost-control measures at Tesla (TSLA), capping employee spending on third-party AI tokens at $200 per week. According to internal memos, any expenditure above this limit now requires explicit managerial approval.
Crucially, the cap excludes beta versions of products from xAI, Musk’s artificial intelligence startup. Employees are being encouraged to move their workflows to Grok 4.5, which launched earlier this week. This shift is seen as an effort to consolidate AI development within Musk's ecosystem while curbing escalating costs from platforms like Anthropic and OpenAI.
Coca-Cola Consolidated Issues Q3 Dividend
Coca-Cola Consolidated (COKE), the largest independent Coca-Cola bottler in the U.S., announced a third-quarter dividend of $0.25 per share. The dividend is payable on August 7, 2026, to stockholders of record as of July 24, 2026.
The announcement reinforces the company's long-standing commitment to shareholder returns, marking its 55th consecutive year of payments. While the stock has faced a 10% decline over the past week, it remains up significantly over the past year, supported by a 17% increase in net sales reported in the first quarter of 2026.
Federal Reserve Releases Weekly H.8 Data
The Federal Reserve has released its weekly H.8 statistical release, providing updated data on the assets and liabilities of commercial banks in the U.S. for the period ending early July. The report is a critical indicator for economists monitoring credit conditions and liquidity shifts within the domestic banking system.
Recent trends in the H.8 data show a steady expansion in bank credit and securities holdings, though commercial and industrial loans have shown volatility. Investors utilize this high-frequency data to gauge the impact of current interest rate levels on bank balance sheets and overall economic lending activity.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.